mdCurrent Conference Report: 64th American Academy of Neurology Annual Meeting Data from 2 major phase 3 trials have demonstrated that progression to clinically definite multiple sclerosis (MS) can be prevented or delayed with early rather than delayed therapy. Two regimens of subcutaneous interferon beta-1a (IFNb) were evaluated in patients who…
Read more »
mdCurrent Conference Report: 64th American Academy of Neurology Annual Meeting A novel strategy to reduce the motor complications associated with fluctuating blood levels of levodopa in patients with Parkinson’s disease was associated with clinically meaningful improvements in disease control, according to the authors of a double-blind trial. Undertaken in patients…
Read more »
mdCurrent Conference Report: 64th American Academy of Neurology Annual Meeting Follow-up data out to 24 months for the first oral disease modifying therapy (DMT) licensed for treatment of multiple sclerosis (MS) continues to suggest that the efficacy and safety rivals that of the injectable agents that have been the MS…
Read more »
mdCurrent Conference Report: 64th American Academy of Neurology Annual Meeting A major multicenter study undertaken in restless leg syndrome (RLS) demonstrated greater efficacy for the alpha-2-delta ligand pregabalin than the dopamine agonist pramipexole, which has been widely regarded until now as the first-line treatment. In the study, presented at the…
Read more »
indicates a Peer-Reviewed Article
Diabetic neuropathy may be linked to metabolic risk factors
Neuropathy is a common, disabling complication of diabetes, and its incidence in India is growing as the prevalence of diabetes—especially type 2 diabetes—continues to rise nationally. India has the world’s largest diabetic population, with an estimated 62 million people diagnosed with the condition, according to the Indian Council of Medical…
Read more »